Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page
- Check2 days agoChange DetectedThe page’s footer “Revision” number was updated from v3.5.2 to v3.5.3, indicating a site/backend version change rather than a change to the clinical trial record content.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded the disease category Squamous cell carcinoma of the head and neck and introduced a Resources section linking the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check38 days agoChange DetectedRevision: v3.5.0 was added and v3.4.3 was removed. The update does not modify study details or user-facing content.SummaryDifference0.1%

- Check45 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3; no visible content changes on the page.SummaryDifference0.1%

- Check73 days agoChange DetectedPage updated to Revision: v3.4.2 and the government funding status notice was removed; no study content or eligibility criteria were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.